College of Medicine – Phoenix, Department of Basic Medical Sciences
When
Where
Where
College of Medicine—Phoenix
Health Sciences Education Building, Room B202
435 N. Fifth St., Phoenix, AZ 85004
CME Details
CME credit provided by the University of Arizona College of Medicine-Tucson
Learning Objectives
- Evaluate the efficacy of bioengineered nanoparticle delivery systems for gene therapies and drug delivery to the lung vasculature in preclinical models of alveolar capillary dysplasia with misalignment of pulmonary veins (ACDMPV), bronchopulmonary dysplasia (BPD) and pediatric acute respiratory distress syndrome (PARDS).
- Assess the ability of pluripotent embryonic stem cells (ESC) to simultaneously differentiate into multiple respiratory cell lineages and form an entire lung structure.
- Demonstrate the advantage of the mouse chimera technology coupled with multiomics to rapidly evaluate human pathogenic mutations in vivo.
Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Arizona College of Medicine – Tucson and the University of Arizona College of Medicine – Phoenix. The University of Arizona College of Medicine –Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Arizona College of Medicine – Tucson designates this live activity for a maximum of one AMA PRA Category 1 credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Relevant Financial Relationships Statement(s):
University of Arizona College of Medicine – Tucson Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.
Name of individual Individual's role in activity Nature of Relationship(s) / Name of Ineligible Company(s)
Frederic Zenhausern, MBA activity director, nothing to disclose, 02/25/2025
Vladimir Kalinichenko, MD faculty, nothing to disclose, 11/05/2025
Presenter Details
Vladimir Kalinichenko, MD, PhD, director, Phoenix Children’s Research Institute at the University of Arizona College of Medicine – Phoenix